En effektivitets- og sikkerhedsundersøgelse med integreret farmakokinetik (PK) og farmakodynamisk vurdering (PD) -vurdering for at sammenligne den foreslåede Ocrelizumab Biosimilar CYB704 og OCREVUS hos deltagere med tilbagefaldende multipel sklerose (RMS)
En randomiseret, dobbeltblind, parallel-gruppeundersøgelse for at sammenligne farmakokinetikken, effektiviteten, farmakodynamikken, sikkerhed og immunogenicitet af CYB704 (foreslået ocrelizumab-biosimilar) og OCREVUS® (EU-autoriseret og US-licenseret) ved deltagere med genindvinding af multiple sclerose (RMS)
The goal of this clinical trial is to learn if drug CYB704, a proposed biosimilar to Ocrevus, works to treat multiple sclerosis in the same way as the reference product Ocrevus(R).
The main questions it aims to answer are:
- Is CYB704 distributed in the body in the same way as the reference product (demonstration of pharmacokinetic (PK) similarity)?
- Does have CYB704 the same treatment effect and side effects as the reference product?
Researchers will compare CYB704 to a Ocrevus (Ocrevus-US and Ocrevus-EU). Participants will:
- Take drug CYB704 or Ocrevus (Ocrevus-US and Ocrevus-EU)
- Visit the clinic for at least 15 treatment visits, checkups and tests
- Will undergo regular magnetic resonance imaging (MRI) examinations
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Banja Luka, Bosnien-Hercegovina
- Sandoz Investigational Site
-
Bihać, Bosnien-Hercegovina
- Sandoz Investigational Site
-
Sarajevo, Bosnien-Hercegovina
- Sandoz Investigational Site
-
Sarajevo, Bosnien-Hercegovina
- Sandoz Investigational Site 2
-
-
-
-
-
Pleven, Bulgarien
- Sandoz Investigational Site
-
Plovdiv, Bulgarien
- Sandoz Investigational Site
-
Plovdiv, Bulgarien
- Sandoz Investigational Site 2
-
Sofia, Bulgarien
- Sandoz Investigational Site 2
-
Sofia, Bulgarien
- Sandoz Investigational Site 3
-
Sofia, Bulgarien
- Sandoz Investigational Site
-
Sofia, Bulgarien
- Sandoz Investigational Site 4
-
Sofia, Bulgarien
- Sandoz Investigational Site 5
-
-
-
-
Florida
-
Maitland, Florida, Forenede Stater, 32751
- Sandoz Investigational Site
-
Ormond Beach, Florida, Forenede Stater, 32174
- Sandoz Investigational Site
-
-
-
-
-
Rustavi, Georgien
- Sandoz Investigational Site
-
Tbilisi, Georgien
- Sandoz Investigational Site
-
Tbilisi, Georgien
- Sandoz Investigational Site 2
-
Tbilisi, Georgien
- Sandoz Investigational Site 3
-
Tbilisi, Georgien
- Sandoz Investigational Site 4
-
Tbilisi, Georgien
- Sandoz Investigational Site 5
-
Tbilisi, Georgien
- Sandoz Investigational Site 6
-
Tbilisi, Georgien
- Sandoz Investigational Site 7
-
Tbilisi, Georgien
- Sandoz Investigational Site 8
-
-
-
-
-
Varaždin, Kroatien
- Sandoz Investigational Site
-
Zagreb, Kroatien
- Sandoz Investigational Site
-
-
-
-
-
Shtip, Nordmakedonien
- Sandoz Investigational Site
-
Skopje, Nordmakedonien
- Sandoz Investigational Site
-
-
-
-
-
Bydgoszcz, Polen
- Sandoz Investigational Site
-
Katowice, Polen
- Sandoz Investigational Site
-
Katowice, Polen
- Sandoz Investigational Site 2
-
Lodz, Polen
- Sandoz Investigational Site
-
Lublin, Polen
- Sandoz Investigational Site
-
Lublin, Polen
- Sandoz Investigational Site 2
-
Nowa Sól, Polen
- Sandoz Investigational Site
-
Poznan, Polen
- Sandoz Investigational Site
-
Poznan, Polen
- Sandoz Investigational Site 2
-
Szczecin, Polen
- Sandoz Investigational Site
-
Warsaw, Polen
- Sandoz Investigational Site
-
Zabrze, Polen
- Sandoz Investigational Site
-
-
-
-
-
Belgrade, Serbien
- Sandoz Investigational Site
-
Niš, Serbien
- Sandoz Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Diagnosis of RMS (relapsing remitting multiple sclerosis (MS) or active secondary progressive MS)
- Evidence of recent disease activity as defined in study protocol
- Expanded Disability Status scale score of 0 to 5.5 (inclusive) at screening
- Neurological stability (no new signs or symptoms referable to Central Nervous System (CNS) within 30 days before both screening and first study treatment
Exclusion Criteria:
- Diagnosis of primary progressive MS
- Disease duration of more than 10 years in participants with an Expanded Disability Status Scale (EDSS) ≤2.0 at screening
- Inability to complete an MRI or contraindication to gadolinium administration
- History of allergic or anaphylactic reactions to ocrelizumab or one of the premedications (methylprednisolone or equivalent corticosteroid, antihistamine, antipyretic)
- Pregnant participants
- Current or history of medical conditions as outlined in the study protocol
- Prohibited medications (current and history) as outlined in the study protocol
- Abnormal laboratory blood values as outlined in the study protocol
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: CYB704
Drug: CYB704 (Ocrelizumab) Patients will be dosed 300 mg on day 1 and day 15. Subsequent dose of 600 mg will be administered 24 weeks after the initial dose. |
Intravenous Infusion
Andre navne:
|
|
Aktiv komparator: Ocrevus-US/Ocrevus-EU
Drug: Ocrevus-US/Ocrevus-EU Patients will be dosed 300 mg on day 1 and day 15 with Ocrevus-US. Subsequent dose of 600 mg Ocrevus-EU will be administered 24 weeks after the initial dose. |
Intravenous Infusion
Andre navne:
Intravenous Infusion
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Area under the concentration time curve
Tidsramme: Week 1 - 3, week 3 - 25
|
Demonstrate similar PK between Ocrevus and CYB704 |
Week 1 - 3, week 3 - 25
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Area under the plasma concentration versus time curve (AUC)
Tidsramme: Week 1 - 25
|
Compare PK between Ocrevus and CYB704 |
Week 1 - 25
|
|
Peak Plasma Concentration (Cmax)
Tidsramme: Day 1 and Day 15
|
Demonstrate similar PK between Ocrevus and CYB704 |
Day 1 and Day 15
|
|
CD19+ B-cell count
Tidsramme: Up to 48 weeks
|
Compare PD between Ocrevus and CYB704 |
Up to 48 weeks
|
|
Number of new T1 GdE lesions on brain MRI scans
Tidsramme: Up to 48 weeks
|
Compare efficacy between Ocrevus and CYB704 |
Up to 48 weeks
|
|
Number of T1 GdE lesions
Tidsramme: Up to 48 weeks
|
Compare efficacy between Ocrevus and CYB704 |
Up to 48 weeks
|
|
Number of new/enlarging T2 lesions
Tidsramme: Up to 48 weeks
|
Compare efficacy between Ocrevus and CYB704 |
Up to 48 weeks
|
|
Number of combined unique active lesions
Tidsramme: Up to 48 weeks
|
Compare efficacy between Ocrevus and CYB704 |
Up to 48 weeks
|
|
Annualized Relapse Rate
Tidsramme: Up to 48 weeks
|
Compare efficacy between Ocrevus and CYB704 |
Up to 48 weeks
|
|
Treatment emergent Adverse Events and Serious Adverse Events
Tidsramme: Up to 48 weeks
|
Compare safety between Ocrevus and CYB704 |
Up to 48 weeks
|
|
Rate of patients with anti-drug antibodies
Tidsramme: Up to 48 weeks
|
Compare immunogenicity between Ocrevus and CYB704 |
Up to 48 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CCYB704A12301
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .